scholarly journals Automatic removal of phase aberration in holographic microscopy for drug sensitivity detection of ovarian cancer cells

OSA Continuum ◽  
2020 ◽  
Vol 3 (7) ◽  
pp. 1856 ◽  
Author(s):  
Che Leiping ◽  
Wen Xiao ◽  
Li Xiaoping ◽  
Jinjin Liu ◽  
Feng Pan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells ◽  
Phase Aberration ◽  
Holographic Microscopy ◽  
Automatic Removal ◽  
Sensitivity Detection

scholarly journals HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way

2019 ◽  
Vol 39 (3) ◽  
Author(s):  
Wenxiang Wang ◽  
Yuxia Gao ◽  
Jing Hai ◽  
Jing Yang ◽  
Shufeng Duan
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Stem Cell ◽  
Cancer Stem Cells ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells ◽  
Her2 Overexpression ◽  
Her2 Positive ◽  
Ovarian Cancer Stem Cells

Abstract Increasing evidence shows that cancer stem cells are responsible for drug resistance and relapse of tumors. In breast cancer, human epidermal growth factor receptor 2 (HER2) induces Herceptin resistance by inducing cancer stem cells. In the present study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. First, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24− population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells. Second, we found that NFκB inhibition by specific inhibitor JSH23 or siRNA targetting subunit p65 dramatically impaired the induction of ovarian cancer stem cells by HER2, indicating that NFκB mediated HER2-induced ovarian cancer stem cells. Third, we found that HER2 KD significantly attenuated the tumorigenicity of ovarian cancer cells. Further, we found that HER2 inhibition increased drastically the sensitivity of ovarian cancer cells to doxorubicin (DOX) or paclitaxel (PTX). Finally, we examined the correlation between HER2 status and stem cell-related genes expression in human ovarian tumor tissues, and found that expressions of OCT4, COX2, and Nanog were higher in HER2 positive tumors than in HER2 negative tumors. Consistently, the 5-year tumor-free survival rate of HER2 positive patients was dramatically lower than HER2 negative patients. Taken together, our data indicate that HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property.

Abstract 3377: Glutamine mediated aggressiveness and drug sensitivity in ovarian cancer cells

2014 ◽  
Author(s):  
Lifeng Yang ◽  
Tyler J. Moss ◽  
Juan C. Marini ◽  
Selanere Mangala ◽  
Stephen Wahlig ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells

scholarly journals miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

2015 ◽  
Vol 14 (1) ◽  
Author(s):  
Marijn T. M. van Jaarsveld ◽  
Patricia F. van Kuijk ◽  
Antonius W. M. Boersma ◽  
Jozien Helleman ◽  
Wilfred F. van IJcken ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Mapk Pathway ◽  
Ovarian Cancer Cells

scholarly journals Outcome in serous ovarian cancer is not associated with LATS expression

2019 ◽  
Vol 145 (11) ◽  
pp. 2737-2749 ◽  
Author(s):  
Céline Montavon ◽  
Gregor R. Stricker ◽  
Andreas Schoetzau ◽  
Viola Heinzelmann-Schwarz ◽  
Francis Jacob ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Protein Expression ◽  
Ovarian Carcinoma ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells ◽  
Data Sets ◽  
Serous Ovarian Cancer ◽  
Transcriptomic Data ◽  
Poor Outcome

Abstract Background Large tumor suppressor (LATS) proteins are putative tumor suppressors and poorly expressed associated with poor outcome in many cancers. A recent immunohistochemistry study showed that LATS protein expression correlated with poor outcome in serous ovarian cancer. Materials and methods We analyzed LATS expression in various ovarian cancer transcriptomic data sets and immunohistochemically assessed LATS protein expression in a Swiss ovarian tumor cohort. Results were compared to clinicopathological characteristics and outcome. We also compared LATS protein expression in serous ovarian cancer cell lines to their EMT status (Western blotting) and drug sensitivity (MTT assay). Results The analysis of 15 different transcriptomic data sets showed that LATS2 was associated with poorer outcome, while LATS1 was irrelevant (HR = 1.19 and HR = 1.00, respectively). The TCGA-RNASeqV2 data set showed that low LATS1 and LATS2 were associated with better survival in serous ovarian carcinoma. Despite heterogeneity among the different data sets, LATS expression is not an indicator of survival in serous ovarian cancer and LATS2 expression may even be tumorigenic. LATS expression was neither associated with survival nor with the stage and grade in the Swiss cohort. It was low in cystadenoma, intermediate in carcinoma, and high in borderline tumors and was higher in serous than mucinous ovarian carcinoma. LATS protein expression extent was comparable in epithelial-, intermediate-, and mesenchymal-type ovarian cancer cells and was not associated with drug sensitivity. Conclusion These results are largely incompatible with a tumor-suppressive function of LATS in ovarian cancer, and LATS protein level is also not an indicator for drug sensitivity and EMT status of ovarian cancer cells.

scholarly journals The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

Oncogene ◽  
1997 ◽  
Vol 15 (5) ◽  
pp. 537-547 ◽  
Author(s):  
Mark D Pegram ◽  
Richard S Finn ◽  
Karo Arzoo ◽  
Malgorzata Beryt ◽  
Richard J Pietras ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells ◽  
Chemotherapeutic Drug ◽  
Human Breast ◽  
Breast And Ovarian Cancer ◽  
Her 2
Sign in / Sign up

Export Citation Format

Share Document